HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wei Feng Shen Selected Research

Glycated Serum Albumin

11/2013Association of increased serum glycated albumin levels with low coronary collateralization in type 2 diabetic patients with stable angina and chronic total occlusion.
7/2013Impact of elevated serum glycated albumin levels on contrast-induced acute kidney injury in diabetic patients with moderate to severe renal insufficiency undergoing coronary angiography.
1/2012Glycated albumin is superior to hemoglobin A1c for evaluating the presence and severity of coronary artery disease in type 2 diabetic patients.
10/2009Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus.
7/2007Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients.
12/2006Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wei Feng Shen Research Topics

Disease

27Coronary Artery Disease (Coronary Atherosclerosis)
01/2019 - 12/2006
23Type 2 Diabetes Mellitus (MODY)
11/2020 - 12/2006
18Cardiovascular Diseases (Cardiovascular Disease)
01/2020 - 06/2008
11Myocardial Infarction
01/2022 - 06/2008
10Atherosclerosis
01/2019 - 12/2006
9Pathologic Constriction (Stenosis)
01/2022 - 01/2009
8ST Elevation Myocardial Infarction
01/2020 - 06/2008
8Hypertension (High Blood Pressure)
11/2019 - 07/2007
8Inflammation (Inflammations)
11/2019 - 01/2016
5Stable Angina
12/2016 - 11/2013
5Thrombosis (Thrombus)
03/2015 - 01/2009
4Heart Failure
01/2021 - 04/2011
4Infarction (Infarctions)
03/2017 - 06/2008
4Atherosclerotic Plaque (Atheroma)
06/2016 - 06/2010
4Renal Insufficiency (Renal Failure)
07/2013 - 07/2007
3Death (Near-Death Experience)
01/2022 - 10/2012
3Diabetes Mellitus
10/2017 - 06/2011
3Hyperplasia
01/2017 - 05/2010
2Insulin Resistance
11/2019 - 01/2019
2Diabetes Complications
11/2019 - 07/2009
2Ischemia
12/2016 - 08/2011
2Fibrosis (Cirrhosis)
10/2016 - 04/2008
2Necrosis
06/2016 - 09/2012
2Acute Kidney Injury (Acute Renal Failure)
07/2013 - 11/2012
2Coronary Stenosis (Coronary Artery Stenosis)
07/2007 - 07/2007
1Stroke (Strokes)
01/2022
1Sclerosis
01/2020
1Systolic Heart Failure
12/2019
1Glucose Intolerance
01/2019
1Diabetic Nephropathies (Diabetic Nephropathy)
10/2017
1Vascular System Injuries
12/2016
1Coronary Occlusion
03/2016

Drug/Important Bio-Agent (IBA)

13omega-Chloroacetophenone (Mace)IBA
01/2022 - 06/2008
12AlbuminsIBA
11/2018 - 12/2006
10Proteins (Proteins, Gene)FDA Link
01/2019 - 07/2007
9C-Reactive ProteinIBA
01/2016 - 12/2006
8Receptor for Advanced Glycation End ProductsIBA
03/2017 - 10/2008
7Phenobarbital (Luminal)FDA Link
01/2020 - 07/2007
6Glycated Serum AlbuminIBA
11/2013 - 12/2006
5oxidized low density lipoproteinIBA
01/2019 - 03/2011
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2018 - 07/2007
5Sirolimus (Rapamycin)FDA Link
10/2015 - 01/2009
5Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
11/2013 - 01/2012
4Biomarkers (Surrogate Marker)IBA
01/2020 - 08/2010
4HDL LipoproteinsIBA
12/2019 - 05/2015
4AdipokinesIBA
11/2019 - 01/2016
3Apolipoproteins E (ApoE)IBA
01/2019 - 06/2016
3CytokinesIBA
01/2019 - 01/2014
3HDL CholesterolIBA
01/2019 - 08/2009
3Reactive Oxygen Species (Oxygen Radicals)IBA
03/2017 - 03/2013
3Tirofiban (Aggrastat)FDA Link
03/2015 - 06/2008
2Tissue Plasminogen Activator (Alteplase)FDA Link
01/2020 - 08/2010
2Glucose (Dextrose)FDA LinkGeneric
01/2020 - 01/2019
2Aryldialkylphosphatase (Paraoxonase)IBA
12/2019 - 05/2015
2Cystatin CIBA
01/2018 - 01/2015
2Peptides (Polypeptides)IBA
12/2017 - 09/2012
2HMGB2 ProteinIBA
03/2017 - 01/2017
2vasostatin IIIBA
10/2016 - 09/2012
2Apolipoprotein A-I (Apolipoprotein A1)IBA
05/2015 - 05/2013
2Platelet Membrane GlycoproteinsIBA
03/2015 - 06/2008
2Indicators and Reagents (Reagents)IBA
07/2013 - 01/2012
2Streptozocin (Streptozotocin)FDA Link
03/2013 - 05/2009
2Hemoglobins (Hemoglobin)IBA
01/2012 - 07/2009
2LigandsIBA
08/2011 - 08/2009
2Advanced Glycation End ProductsIBA
06/2011 - 07/2009
2HMGB1 Protein (HMG1)IBA
04/2011 - 08/2009
2Lipoprotein(a)IBA
10/2009 - 07/2007
2human esRAGE proteinIBA
10/2009 - 07/2009
1Chromogranin BIBA
01/2021
1AntioxidantsIBA
12/2019
1arylesteraseIBA
12/2019
1MicroRNAs (MicroRNA)IBA
11/2019
1SodiumIBA
11/2019
1CholesterolIBA
01/2019
1LDL CholesterolIBA
01/2019
1Triglycerides (Triacylglycerol)IBA
01/2019
1VimentinIBA
01/2019
1LDL Lipoproteins (beta Lipoproteins)IBA
11/2018
1chemotactic factor inactivatorIBA
01/2018
1Apolipoproteins AIBA
10/2017
1apolipoprotein A-IV (apolipoprotein AIV)IBA
10/2017
1Member 3 Group A Nuclear Receptor Subfamily 4IBA
10/2017
1Lysine (L-Lysine)FDA Link
10/2017
1Glyoxal (Ethanedial)IBA
10/2017
1ApolipoproteinsIBA
10/2017
1Serum Amyloid A Protein (Serum Amyloid A)IBA
10/2017
1acetovanillone (apocynin)IBA
03/2017
1CyanatesIBA
12/2016
1homocitrullineIBA
12/2016
1Biological ProductsIBA
06/2016
1Lipoproteins (Lipoprotein)IBA
01/2016
1Toll-Like Receptors (Toll-Like Receptor)IBA
01/2016

Therapy/Procedure

19Stents
01/2022 - 10/2008
16Percutaneous Coronary Intervention
11/2020 - 02/2007
4Drug-Eluting Stents
02/2017 - 02/2007
3Therapeutics
03/2015 - 06/2008
2Intraperitoneal Injections
01/2019 - 06/2016
2Coronary Artery Bypass (Coronary Artery Bypass Surgery)
03/2016 - 02/2007
1Oral Administration
12/2016
1Endarterectomy (Thromboendarterectomy)
06/2016